ALAMEDA, Calif., June 12 /PRNewswire-FirstCall/ -- Avigen, Inc. (Nasdaq: AVGN - News) today announced approval to initiate a Phase IIa exploratory therapeutic clinical trial with AV411 (ibudilast) at the Royal Adelaide Hospital in Adelaide, Australia to assess safety, tolerability and preliminary indication of efficacy in neuropathic pain patients. The Phase IIa trial is a placebo-controlled, double-blinded study primarily in patients suffering from diabetic neuropathy. This dose-escalating trial is also designed to generate data to support a larger U.S. clinical trial which Avigen currently anticipates will be initiated in 2007.
